BioCentury | Jul 30, 2020
Product Development

Finding immunosuppression sweet spot could be next up for COVID-19 after second IL-6 failure

...tocilizumab (Generic), RoActemra (Informal), MRA (Informal), Actemra (Informal) lenzilumab (KB003) Humanigen Inc. Interleukin-6 (IL-6) Granulocyte macrophage colony-stimulating factor (GM-CSF) (CSF2) Granulocyte macrophage colony-stimulating factor (GM-CSF) receptor (CSF2RA) (GMR) (CD116) (GMCSFR) covid-19 cov19count immunosuppression chs2020 cov19count...
BioCentury | Jun 19, 2020
Product Development

InflaRx, Kiniksa anti-inflammatory mAbs yield trend toward lower COVID-19 mortality, plus Sinopharm reports antibody readout from vaccine trial

...IFX-1 InflaRx N.V. Kiniksa Pharmaceuticals Ltd. China National Pharmaceutical Group Corp. (Sinopharm) Chembio Diagnostics Inc. Ortho Clinical Diagnostics Inc. Complement 5a (C5a) Granulocyte macrophage colony-stimulating factor (GM-CSF) receptor (CSF2RA) (GMR) (CD116) (GMCSFR) cov19count COVID-19 cov19count...
Items per page:
1 - 2 of 2